9 terminated. 9 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 3 | 4 | Terminated 4 |
| Phase 1 | 3 | Terminated 3 |
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa RNA antisense oligonucleotide for intravitreal injection - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Terminated | Laboratoires Thea | 21 | 2021-09-16 | 2024-08-07 |
| A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention BHV-3500 (zavegepant), Placebo - Migraine | Phase 2 / Phase 3 | Terminated | Pfizer | 1753 | 2021-03-26 | 2025-03-27 |
| A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. KSI-301, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 2 / Phase 3 | Terminated | Kodiak Sciences Inc | 559 | 2019-10-08 | 2024-07-18 |
| Extension Study to Study PQ-110-001 (NCT03140969) QR-110 - Leber Congenital Amaurosis 10, Blindness | Phase 1 / Phase 2 | Terminated | Laboratoires Thea | 9 | 2019-05-13 | 2024-10-15 |
| Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene AAV2/5-hPDE6B - Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | eyeDNA Therapeutics | 19 | 2017-11-06 | 2025-12-18 |
| Fluoxetine for Visual Recovery After Ischemic Stroke Fluoxetine, Placebo - Acute Stroke, Visual Field Loss | Phase 2 | Terminated | Bogachan Sahin | 17 | 2016-05-01 | 2021-10-13 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B SAR421869 - Usher Syndrome, Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | Sanofi | 9 | 2012-03-26 | 2022-04-28 |
Eye Diseases (6) · Retinal Diseases (6) · Retinitis Pigmentosa (5) · Eye Diseases, Hereditary (4) · Usher Syndromes (4) · Eye Abnormalities (3) · Retinal Degeneration (2) · Blindness (1) · Genetic Diseases, Inborn (1) · Hemianopsia (1) · Hyperacusis (1) · Ischemic Stroke (1) · Leber Congenital Amaurosis (1) · Leber Congenital Amaurosis 10 (1)
Nervous System Diseases (9) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Neurologic Manifestations (8) · Sensation Disorders (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Blindness (5) · Congenital Abnormalities (5) · Ear Diseases (5) · Genetic Diseases, Inborn (5) · Hearing Disorders (5) · Otorhinolaryngologic Diseases (5) · Abnormalities, Multiple (4) · Deaf-Blind Disorders (4) · Deafness (4)
Intravitreal Injections (3) · Fluoxetine (1) · aflibercept (1)
Laboratoires Thea (4) · Bogachan Sahin (1) · Kodiak Sciences Inc (1) · Pfizer (1) · Sanofi (1) · eyeDNA Therapeutics (1)
United States (8) · France (3) · Germany (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Czechia (1) · Latvia (1) · Netherlands (1) · Poland (1) · Slovakia (1) · Spain (1)
Jose-Alain Sahel, MD, PhD (1) · Pablo Velazquez-Martin, MD (1) · Richard Weleber, MD (1)
PMID 22828504, PMID 24705452, PMID 26857842, PMID 30646425, PMID 33230035, PMID 36166771, PMID 42645743
2016 (1), 2018 (1)